Cargando…

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction

Sildenafil was the first orally administered phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. Its successful introduction into clinical practice was soon followed by the launch of two other phosphodiesterase-5 inhibitors: vardenafil and tadalafil. The plethora of cho...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannitsas, Konstantinos, Konstantinopoulos, Angelis, Patsialas, Christos, Perimenis, Petros
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770422/
https://www.ncbi.nlm.nih.gov/pubmed/19920956
_version_ 1782173655845830656
author Giannitsas, Konstantinos
Konstantinopoulos, Angelis
Patsialas, Christos
Perimenis, Petros
author_facet Giannitsas, Konstantinos
Konstantinopoulos, Angelis
Patsialas, Christos
Perimenis, Petros
author_sort Giannitsas, Konstantinos
collection PubMed
description Sildenafil was the first orally administered phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. Its successful introduction into clinical practice was soon followed by the launch of two other phosphodiesterase-5 inhibitors: vardenafil and tadalafil. The plethora of choices made the question “which PDE-5 inhibitor?” relevant for patients and clinicians. Despite the lack of head-to-head comparative trials it is widely accepted that there are no significant differences in their safety and efficacy. Therefore a number of studies set out to determine which of the inhibitors patients would prefer and reasons for that preference. The majority of published trials show a preference for tadalafil. Others have argued that preference trials have several methodological flaws and data favoring tadalafil with its long duration of action do not reflect real-life prescription filling and sales figures. But even if one of the available PDE-5 inhibitors is chosen to treat erectile dysfunction what is the long-term compliance? A significant percentage of men initiating treatment switch between inhibitors or discontinue therapy. Reasons for that seem to often be unrelated to efficacy or tolerability and include emotional and social factors determining couples’ and individuals’ sexual and treatment seeking behavior.
format Text
id pubmed-2770422
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27704222009-11-17 Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction Giannitsas, Konstantinos Konstantinopoulos, Angelis Patsialas, Christos Perimenis, Petros Patient Prefer Adherence Review Sildenafil was the first orally administered phosphodiesterase-5 inhibitor approved for the treatment of erectile dysfunction. Its successful introduction into clinical practice was soon followed by the launch of two other phosphodiesterase-5 inhibitors: vardenafil and tadalafil. The plethora of choices made the question “which PDE-5 inhibitor?” relevant for patients and clinicians. Despite the lack of head-to-head comparative trials it is widely accepted that there are no significant differences in their safety and efficacy. Therefore a number of studies set out to determine which of the inhibitors patients would prefer and reasons for that preference. The majority of published trials show a preference for tadalafil. Others have argued that preference trials have several methodological flaws and data favoring tadalafil with its long duration of action do not reflect real-life prescription filling and sales figures. But even if one of the available PDE-5 inhibitors is chosen to treat erectile dysfunction what is the long-term compliance? A significant percentage of men initiating treatment switch between inhibitors or discontinue therapy. Reasons for that seem to often be unrelated to efficacy or tolerability and include emotional and social factors determining couples’ and individuals’ sexual and treatment seeking behavior. Dove Medical Press 2008-02-02 /pmc/articles/PMC2770422/ /pubmed/19920956 Text en © 2008 Giannitsas et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Giannitsas, Konstantinos
Konstantinopoulos, Angelis
Patsialas, Christos
Perimenis, Petros
Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
title Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
title_full Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
title_fullStr Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
title_full_unstemmed Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
title_short Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
title_sort preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770422/
https://www.ncbi.nlm.nih.gov/pubmed/19920956
work_keys_str_mv AT giannitsaskonstantinos preferenceforandadherencetooralphosphodiesterase5inhibitorsinthetreatmentoferectiledysfunction
AT konstantinopoulosangelis preferenceforandadherencetooralphosphodiesterase5inhibitorsinthetreatmentoferectiledysfunction
AT patsialaschristos preferenceforandadherencetooralphosphodiesterase5inhibitorsinthetreatmentoferectiledysfunction
AT perimenispetros preferenceforandadherencetooralphosphodiesterase5inhibitorsinthetreatmentoferectiledysfunction